CFDE Data Portal | Search LINC03219

	Label	Description
	LINC03219 Gene (Entity type)	ENSG00000289047 - long intergenic non-protein coding RNA 3219
	GSE199107 tryptophan 6 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE178340 carfilzomib MM1.S 7 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE214931 temozolomide 4 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158552 BRD4 inhibition 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 8 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE99875 everolimus 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173483 nutlin-3 U2OS 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

LINC03219

ENSG00000289047 - long intergenic non-protein coding RNA 3219

GSE199107 tryptophan 6 v 7 human up

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 1 human dn

A Gene Set from LINCS

GSE178340 carfilzomib MM1.S 7 v 9 human dn

A Gene Set from LINCS

GSE214931 temozolomide 4 v 0 human up

A Gene Set from LINCS

GSE158552 BRD4 inhibition 2 v 0 human dn

A Gene Set from LINCS

GSE239844 crizotinib 8 v 10 human dn

A Gene Set from LINCS

GSE99875 everolimus 2 v 0 human dn

A Gene Set from LINCS

GSE173483 nutlin-3 U2OS 1 v 0 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.